The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial

David P. Dearnaley; Daniel R. Saltzstein; John E. Sylvester; Lawrence Karsh; Bryan A. Mehlhaff; Christopher Pieczonka; James L. Bailen; Hongliang Shi; Zhan Ye; Hélène M. Faessel; Huamao Lin; Yanyan Zhu; Fred Saad; David B. MacLean; Neal D. Shore

doi:10.1016/j.eururo.2020.03.001

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial

European Urology ◽

10.1016/j.eururo.2020.03.001 ◽

2020 ◽

Vol 78 (2) ◽

pp. 184-192 ◽

Cited By ~ 3

Author(s):

David P. Dearnaley ◽

Daniel R. Saltzstein ◽

John E. Sylvester ◽

Lawrence Karsh ◽

Bryan A. Mehlhaff ◽

...

Keyword(s):

External Beam Radiotherapy ◽

Gonadotropin Releasing Hormone ◽

External Beam ◽

Intermediate Risk ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Parallel Group ◽

Risk Prostate Cancer ◽

Gonadotropin Releasing Hormone Receptor

Download Full-text

Trimodal treatment for localized high risk prostate cancer A design of a phase II, multi-center, open-label, randomized, parallel-group study to compare the effectiveness and safety of radical prostatectomy, external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) versus EBRT and ADT for patients with localized high risk prostate cancer.

Principles and Practice of Clinical Research Journal ◽

10.21801/ppcrj.2020.61.2 ◽

2020 ◽

Vol 6 (1) ◽

pp. 3-8

Author(s):

Roberto Paz-Manrique ◽

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

External Beam Radiotherapy ◽

External Beam ◽

Open Label ◽

High Risk Prostate Cancer ◽

Parallel Group ◽

Risk Prostate Cancer ◽

Trimodal Treatment

Download Full-text

Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00196-0 ◽

2021 ◽

Author(s):

Arjun Sahgal ◽

Sten D Myrehaug ◽

Shankar Siva ◽

Giuseppina L Masucci ◽

Pejman J Maralani ◽

...

Keyword(s):

Stereotactic Body Radiotherapy ◽

External Beam Radiotherapy ◽

Spinal Metastases ◽

External Beam ◽

Phase 2 ◽

Open Label ◽

Randomised Controlled

Download Full-text

Successful Phase 2 Trial of Ultrafocal Brachytherapy for Low/Intermediate Risk Prostate Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2017.06.1166 ◽

2017 ◽

Vol 99 (2) ◽

pp. E235-E236 ◽

Cited By ~ 2

Author(s):

P. Graff ◽

B. Malavaud ◽

D. Portalez ◽

T. Brun ◽

R. Aziza ◽

...

Keyword(s):

Prostate Cancer ◽

Intermediate Risk ◽

Phase 2 ◽

Phase 2 Trial ◽

Risk Prostate Cancer ◽

Successful Phase

Download Full-text

Randomised Phase II Feasibility Trial of Image-guided External Beam Radiotherapy With or Without High Dose Rate Brachytherapy Boost in Men with Intermediate-risk Prostate Cancer (CCTG PR15/ NCT01982786)

Clinical Oncology ◽

10.1016/j.clon.2018.05.007 ◽

2018 ◽

Vol 30 (9) ◽

pp. 527-533 ◽

Cited By ~ 3

Author(s):

E. Vigneault ◽

G. Morton ◽

W.R. Parulekar ◽

T.M. Niazi ◽

C.W. Springer ◽

...

Keyword(s):

Prostate Cancer ◽

External Beam Radiotherapy ◽

High Dose Rate ◽

Feasibility Trial ◽

High Dose ◽

External Beam ◽

Intermediate Risk ◽

Image Guided ◽

Risk Prostate Cancer ◽

Brachytherapy Boost

Download Full-text

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30011-5 ◽

2020 ◽

Vol 21 (4) ◽

pp. 571-580 ◽

Cited By ~ 33

Author(s):

Shukui Qin ◽

Zhenggang Ren ◽

Zhiqiang Meng ◽

Zhendong Chen ◽

Xiaoli Chai ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Advanced Hepatocellular Carcinoma ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Parallel Group ◽

Previously Treated

Download Full-text

Absolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) appears predictive of disease control after high dose rate brachytherapy and external beam radiotherapy in intermediate risk prostate cancer

Radiotherapy and Oncology ◽

10.1016/j.radonc.2019.03.007 ◽

2019 ◽

Vol 135 ◽

pp. 170-177 ◽

Cited By ~ 2

Author(s):

K. Martell ◽

L.C. Mendez ◽

H. Chung ◽

C.L. Tseng ◽

L. Zhang ◽

...

Keyword(s):

Prostate Cancer ◽

Disease Control ◽

Dose Rate ◽

External Beam Radiotherapy ◽

High Dose Rate ◽

High Dose ◽

External Beam ◽

Intermediate Risk ◽

Gleason Pattern ◽

Risk Prostate Cancer

Download Full-text

90: Population-Based Analysis of Treatment Factors and Outcomes of Combined Modality Therapy with Low-Dose-Rate Brachytherapy (LDR-PB) Implant with External Beam Radiotherapy (EBRT) for High and Intermediate-Risk Prostate Cancer

Radiotherapy and Oncology ◽

10.1016/s0167-8140(20)30982-8 ◽

2020 ◽

Vol 150 ◽

pp. S40-S41

Author(s):

Justin Oh ◽

Ingrid Spadinger ◽

Vincent Lapointe ◽

James Morris

Keyword(s):

Prostate Cancer ◽

Low Dose ◽

Combined Modality Therapy ◽

External Beam Radiotherapy ◽

Population Based ◽

External Beam ◽

Intermediate Risk ◽

Low Dose Rate ◽

Risk Prostate Cancer ◽

Low Dose Rate Brachytherapy

Download Full-text

Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial

The Lancet ◽

10.1016/s0140-6736(09)62163-2 ◽

2010 ◽

Vol 375 (9717) ◽

pp. 816-823 ◽

Cited By ~ 649

Author(s):

RA Nout ◽

VTHBM Smit ◽

H Putter ◽

IM Jürgenliemk-Schulz ◽

JJ Jobsen ◽

...

Keyword(s):

Endometrial Cancer ◽

External Beam Radiotherapy ◽

Randomised Trial ◽

External Beam ◽

Intermediate Risk ◽

Open Label

Download Full-text

Single-Fraction High-Dose-Rate Brachytherapy and Hypofractionated External Beam Radiotherapy for Men With Intermediate-Risk Prostate Cancer: Analysis of Short- and Medium-Term Toxicity and Quality of Life

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2009.05.054 ◽

2010 ◽

Vol 77 (3) ◽

pp. 811-817 ◽

Cited By ~ 56

Author(s):

Gerard C. Morton ◽

D. Andrew Loblaw ◽

Raxa Sankreacha ◽

Andrea Deabreu ◽

Liying Zhang ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

External Beam Radiotherapy ◽

High Dose Rate ◽

High Dose ◽

External Beam ◽

Intermediate Risk ◽

Medium Term ◽

Risk Prostate Cancer

Download Full-text

Long-Term Oncologic Outcomes of Low Dose Rate Brachytherapy Compared to Hypofractionated External Beam Radiotherapy for Intermediate Risk Prostate Cancer

Brachytherapy ◽

10.1016/j.brachy.2019.04.038 ◽

2019 ◽

Vol 18 (3) ◽

pp. S15-S16

Author(s):

Noelia Sanmamed ◽

Lisa Joseph ◽

Juanita Crook ◽

Jette Borg ◽

Peter Chung ◽

...

Keyword(s):

Prostate Cancer ◽

Low Dose ◽

External Beam Radiotherapy ◽

Oncologic Outcomes ◽

External Beam ◽

Intermediate Risk ◽

Low Dose Rate ◽

Risk Prostate Cancer ◽

Low Dose Rate Brachytherapy

Download Full-text